Regina Young

Jun 8, 2024 | cell.com | Regina Young |Carl June

HighlightsThe efficacy of chimeric antigen receptor (CAR) T cells targeting solid tumors is constrained by target heterogeneity, treatment-associated toxicities, and immunosuppressive factors in the tumor microenvironment, such as poor T cell infiltration, metabolic stress, and T cell exhaustion. Toxicities associated with CAR T cell therapies can limit administration of therapeutic doses of CAR T cells.